Dynamics of target-mediated drug disposition: Characteristic profiles and parameter identification

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 5, 2012, Pages 429-451

  Peletier, Lambertus A ^a   Gabrielsson, Johan ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Antibodies; Drugdisposition; Michaelis Menten; Quasi equilibrium; Quasi steady state; Receptor; Singular perturbation; Target

Indexed keywords

LIGAND;

ACCURACY; ARTICLE; DRUG INFUSION; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROBABILITY; PROCESS DEVELOPMENT; PROCESS MODEL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; STEADY STATE; SYSTEM ANALYSIS; TARGET MEDIATED DRUG DISPOSITION;

ANIMALS; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84870468930     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9260-6     Document Type: Article

References (25)

1. Shankaran H, Rasat H, Wiley HS (2007) Cell surface receptors for signal transduction and ligand transport: a design principles study. PloS Comput Biol 3(6):986-999
2. Levy G (1994) Pharmacologic target mediated drug disposition. Clin Pharmacol Ther 56:248-252
3. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Phamacodyn 28(6):507-532
4. Michaelis L, Menten ML (1913) Die Kinetik der Invertinwirkung. Biochem Z 49:333-369
5. Sugiyama Y, Hanano M (1989) Receptor-mediated transport of peptide hormones and its importance in the overall hormone disposition in the body. Pharm Res 6(3):192-202
6. Mager DE, Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589-1596
7. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573-591
8. Marathe A, Krzyzanski W, Mager D (2009) Numerical validation of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn 36:199-219
9. Gibiansky L, Gibiansky E (2009) Target-mediated drug disposition model: relationships with indirect response models and application to population PKPD analysis. J Pharmacokinet Pharmacodyn 36: 341-351
10. Meibohm, B (eds) (2006) Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Wiley-VCH Verlag GmbH & Co KGaA, Weinheim
11. Crommelin DJA, Sindelar RD, Meibohm B (eds) (2008) Pharmaceutical biotechnology: fundamentals and applications. Informa Healthcare, New York
12. Lobo E, Hansen RJ, Balthasar JR (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645-2667
13. Mager D (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10
14. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397-420
15. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25-47
16. Krippendorff BF, Kuester K, Kloft C, HuisingaW(2009) Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn 36:239-260
17. Peletier LA, Gabrielsson J (2009) Dynamics of target-mediated drug disposition. Eur J Pharm Sci 38:445-464
18. Ma P (2012) Theoretical considerations of target-mediated drug disposition models: simplifications and approximations. Pharm Res 29:866-882
19. Segel LA (1988) On the validity of the steady state assumption of enzyme kinetics. Bull Math Biol 50(6):579-593
20. Segel LA, Slemrod M (1989) The quasi-steady state assumption: a case study in perturbation. SIAM Rev 31(3):446-477
21. Peletier LA, Benson N, van der Graaf PH (2009) Impact of plasma-protein binding on receptor occupancy: an analytical description. J Theor Biol 256(2):253-262
22. Krzyzanski W, Wyska E (2008) Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volonteers. Naunyn Schmiedebergs Arch Pharmacol 377:637-645
23. Mager DE, Jusko WJ (2002) Receptor-mediated pharmacokinetic/ pharmacodynamic model of interferon-b 1a in humans. Pharm Res 19(10):1537-1543
24. Aston PJ, Derks G, Raji A, Agoram BM, van der Graaf PH (2011) Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol 281(1):113-121
25. Wagner JG (1971) Biopharmaceutics and relevant pharmacokinetics. Drug Intelligence Publications, Hamilton Press, Hamilton